

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESOLUTIONS PASSED AT THE 5TH BOARD MEETING FOR FY2024

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company” and together with its subsidiaries, the “Group”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 10 September 2024, the Company duly convened its 5th board meeting for the financial year ending 31 December 2024 (“FY2024”) through a combination of physical meeting and teleconference. The full board of nine (9) directors was present. The said meeting was convened in compliance with applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were discussed and passed:

1. That the proposed capital injection into Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) by the Company through the transfer of the 100% equity interest in the registered capital of Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) to Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) (the “**Proposed Capital Injection**”), and the proposed entry into a Capital Injection Agreement (津药达仁堂集团股份有限公司对津药太平医药有限公司的增资协议) in relation thereto, as an interested person transaction, be approved;

Mr. Guo Min, Ms. Zhang Mingrui and Ms. Mao Weiwen, being the interested directors, have abstained from voting on this resolution.

Please refer to the separate announcement made by the Company on the same day as this announcement for further information on the Proposed Capital Injection.

2. That the resultant joint venture in Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) (the “**Proposed Joint Venture**”) following the completion of the Proposed Capital Injection, as an interested person transaction, be approved;

Mr. Guo Min, Ms. Zhang Mingrui and Ms. Mao Weiwen, being the interested directors, have abstained from voting on this resolution.

Please refer to the separate announcement made by the Company on the same day as this announcement for further information on the Proposed Joint Venture.

3. That the proposed provision of a guarantee for an amount of up to RMB832,650,000 by the Company for Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) (the “**Proposed Provision of Guarantee**”) following the completion of the Proposed Capital Injection, as an interested person transaction, be approved.

Mr. Guo Min, Ms. Zhang Mingrui and Ms. Mao Weiwen, being the interested directors, have abstained from voting on this resolution.

Please refer to the separate announcement made by the Company on the same day as this announcement for further information on the Proposed Provision of Guarantee.

4. That pursuant to the applicable Company Law and the Articles of Association of the Company, the proposed convening of the 1st extraordinary general meeting of the Company in 2024 (the “**2024 EGM**”) be approved.

The above resolutions No. 1 to No. 3 will be tabled for shareholders’ approval at the Company’s 2024 EGM.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
11 September 2024